Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Van Ranst

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Veterinary Pathology|January 22, 2000
Feline papillomas and papillomavirusesJ P Sundberg, M Van Ranst, R Montali, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2001
Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through JE Fontaine, C Riva, M Peeters, et al.
Clinical and Diagnostic Laboratory Immunology|January 4, 2001
Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assayT Lazzarotto, C Galli, R Pulvirenti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2000
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populationsK Van Laethem, K Van Vaerenbergh, J C Schmit, et al.
AIDS Research and Human Retroviruses|April 18, 2002
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patientsK Van Vaerenbergh, T Harrer, J-C Schmit, et al.
Antiviral Therapy|June 22, 2001
Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in BelgiumK Van Vaerenbergh, L Debaisieux, N De Cabooter, et al.
HIV Medicine|July 30, 2015
Late presentation to HIV testing is overestimated when based on the consensus definitionA Sasse, E Florence, A Pharris, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 4, 2014
Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotavirusesJ Matthijnssens, M Zeller, E Heylen, et al.
AIDS Research and Human Retroviruses|June 30, 2000
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patientsK Van Laethem, J C Schmit, H Pelemans, et al.
The Journal of Infectious Diseases|October 14, 2009
Rotavirus surveillance in europe, 2005-2008: web-enabled reporting and real-time analysis of genotyping and epidemiological dataM Iturriza-Gómara, T Dallman, K Bányai, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Veterinary Pathology|January 22, 2000
Feline papillomas and papillomavirusesJ P Sundberg, M Van Ranst, R Montali, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2001
Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through JE Fontaine, C Riva, M Peeters, et al.
Clinical and Diagnostic Laboratory Immunology|January 4, 2001
Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assayT Lazzarotto, C Galli, R Pulvirenti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2000
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populationsK Van Laethem, K Van Vaerenbergh, J C Schmit, et al.
AIDS Research and Human Retroviruses|April 18, 2002
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patientsK Van Vaerenbergh, T Harrer, J-C Schmit, et al.
Antiviral Therapy|June 22, 2001
Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in BelgiumK Van Vaerenbergh, L Debaisieux, N De Cabooter, et al.
HIV Medicine|July 30, 2015
Late presentation to HIV testing is overestimated when based on the consensus definitionA Sasse, E Florence, A Pharris, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 4, 2014
Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotavirusesJ Matthijnssens, M Zeller, E Heylen, et al.
AIDS Research and Human Retroviruses|June 30, 2000
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patientsK Van Laethem, J C Schmit, H Pelemans, et al.
The Journal of Infectious Diseases|October 14, 2009
Rotavirus surveillance in europe, 2005-2008: web-enabled reporting and real-time analysis of genotyping and epidemiological dataM Iturriza-Gómara, T Dallman, K Bányai, et al.
Pageof 9